These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 29529307)

  • 1. Opportunistic infections in rheumatoid arthritis patients exposed to biologic therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Patarata E; Subesinghe S; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2018 Jun; 57(6):997-1001. PubMed ID: 29529307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Serious infection across biologic-treated patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Rutherford AI; Subesinghe S; Hyrich KL; Galloway JB
    Ann Rheum Dis; 2018 Jun; 77(6):905-910. PubMed ID: 29592917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recurrent serious infections in patients with rheumatoid arthritis-results from the British Society for Rheumatology Biologics Register.
    Subesinghe S; Rutherford AI; Byng-Maddick R; Leanne Hyrich K; Benjamin Galloway J
    Rheumatology (Oxford); 2018 Apr; 57(4):651-655. PubMed ID: 29340619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonserious Infections in Patients With Rheumatoid Arthritis: Results From the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bechman K; Halai K; Yates M; Norton S; Cope AP; ; Hyrich KL; Galloway JB
    Arthritis Rheumatol; 2021 Oct; 73(10):1800-1809. PubMed ID: 33844458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of septic arthritis in patients with rheumatoid arthritis and the effect of anti-TNF therapy: results from the British Society for Rheumatology Biologics Register.
    Galloway JB; Hyrich KL; Mercer LK; Dixon WG; Ustianowski AP; Helbert M; Watson KD; Lunt M; Symmons DP;
    Ann Rheum Dis; 2011 Oct; 70(10):1810-4. PubMed ID: 21784730
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER) study.
    Baddley JW; Winthrop KL; Chen L; Liu L; Grijalva CG; Delzell E; Beukelman T; Patkar NM; Xie F; Saag KG; Herrinton LJ; Solomon DH; Lewis JD; Curtis JR
    Ann Rheum Dis; 2014 Nov; 73(11):1942-8. PubMed ID: 23852763
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Silva-Fernández L; De Cock D; Lunt M; Low AS; Watson KD; ; Symmons DPM; Hyrich KL
    Rheumatology (Oxford); 2018 Sep; 57(9):1533-1540. PubMed ID: 28968862
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson KD; Lunt M; Mercer LK; Hyrich KL; Symmons DP; ;
    Arthritis Care Res (Hoboken); 2010 Jun; 62(6):755-63. PubMed ID: 20535785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Hyrich KL; Watson KD; Lunt M; ; Symmons DP;
    Ann Rheum Dis; 2010 Jun; 69(6):1086-91. PubMed ID: 20444754
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biologic prescribing decisions following serious infection: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Subesinghe S; Rutherford AI; Byng-Maddick R; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2018 Dec; 57(12):2096-2100. PubMed ID: 29986108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The relationship between depression and biologic treatment response in rheumatoid arthritis: An analysis of the British Society for Rheumatology Biologics Register.
    Matcham F; Davies R; Hotopf M; Hyrich KL; Norton S; Steer S; Galloway J
    Rheumatology (Oxford); 2018 May; 57(5):835-843. PubMed ID: 29447376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.
    Silva-Fernández L; Lunt M; Kearsley-Fleet L; Watson KD; Dixon WG; Symmons DP; Hyrich KL;
    Rheumatology (Oxford); 2016 Nov; 55(11):2033-2039. PubMed ID: 27550304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.
    Nisar MK; Rafiq A; Östör AJ
    Clin Rheumatol; 2015 Dec; 34(12):2141-5. PubMed ID: 26497501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased risk of opportunistic infection in early rheumatoid arthritis.
    Kim H; Cho SK; Lee J; Bae SC; Sung YK
    Int J Rheum Dis; 2019 Jul; 22(7):1239-1246. PubMed ID: 31090187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British Society for Rheumatology Biologics Register.
    Dixon WG; Watson K; Lunt M; Hyrich KL; Silman AJ; Symmons DP;
    Arthritis Rheum; 2006 Aug; 54(8):2368-76. PubMed ID: 16868999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is background methotrexate advantageous in extending TNF inhibitor drug survival in elderly patients with rheumatoid arthritis? An analysis of the British Society for Rheumatology Biologics Register.
    Bechman K; Oke A; Yates M; Norton S; Dennison E; Cope AP; Galloway JB
    Rheumatology (Oxford); 2020 Sep; 59(9):2563-2571. PubMed ID: 31998962
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
    Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polypharmacy is associated with treatment response and serious adverse events: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
    Bechman K; Clarke BD; Rutherford AI; Yates M; Nikiphorou E; Molokhia M; Norton S; Cope AP; Hyrich KL; Galloway JB
    Rheumatology (Oxford); 2019 Oct; 58(10):1767-1776. PubMed ID: 30982886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discordant inflammation and pain in early and established rheumatoid arthritis: Latent Class Analysis of Early Rheumatoid Arthritis Network and British Society for Rheumatology Biologics Register data.
    McWilliams DF; Ferguson E; Young A; Kiely PD; Walsh DA
    Arthritis Res Ther; 2016 Dec; 18(1):295. PubMed ID: 27964757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serious infections in patients with rheumatoid arthritis and other immune-mediated connective tissue diseases exposed to anti-TNF or rituximab: data from the Spanish registry BIOBADASER 2.0.
    Cobo-Ibáñez T; Descalzo MÁ; Loza-Santamaría E; Carmona L; Muñoz-Fernández S
    Rheumatol Int; 2014 Jul; 34(7):953-61. PubMed ID: 24414744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.